A Phase III clinical trial shows that elexacaftor added to ivacaftor and tezacaftor improves lung function and quality of life in cystic fibrosis patients with the most common genetic mutation, F508del. The triple therapy, known as Trikafta, could effectively treat 90 percent of people with cystic fibrosis.

Read the whole story at Pediatrics Nationwide: A Major Milestone in Cystic Fibrosis Treatment.